AR021577A1 - Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidos - Google Patents
Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidosInfo
- Publication number
- AR021577A1 AR021577A1 ARP990106239A ARP990106239A AR021577A1 AR 021577 A1 AR021577 A1 AR 021577A1 AR P990106239 A ARP990106239 A AR P990106239A AR P990106239 A ARP990106239 A AR P990106239A AR 021577 A1 AR021577 A1 AR 021577A1
- Authority
- AR
- Argentina
- Prior art keywords
- synthesis
- nucleotides
- prepared
- improved therapeutic
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Preparado con una amplitud terapéutica mejorada, que contiene inhibidores de la síntesis de los nucleotidos. Un preparado que contiene por lo menos uncompuesto que esencialmente impide la circulacion entero-hepática de los inhibidores de la síntesisde los nucleotidos, o que, temporalmente desplazado,antagoniza el efecto de los inhibidores de la síntesis de los nucleotidos, y un inhibidor de la síntesis de los nucleotidos, tal como el Brequinar, elMicofenolatmofetil, el 2-morfolinoetil-(E)-(1,3-dihidro-4-hidroxi-6-metoxi-7-metil-3-oxoisobenzofuran-5-il)-4-metil-4-hexenoato), el Methotrexato, elMizoribine y los compuestos de las formulas (1) o (2): es adecuado para el tratamiento de enfermedades inmunologicas, del cáncer, o en transplantes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19857009A DE19857009A1 (de) | 1998-12-10 | 1998-12-10 | Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021577A1 true AR021577A1 (es) | 2002-07-24 |
Family
ID=7890633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106239A AR021577A1 (es) | 1998-12-10 | 1999-12-07 | Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidos |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1137438B1 (es) |
| JP (1) | JP2002531525A (es) |
| KR (1) | KR20010080729A (es) |
| CN (1) | CN1189214C (es) |
| AR (1) | AR021577A1 (es) |
| AT (1) | ATE218370T1 (es) |
| AU (1) | AU766810B2 (es) |
| BG (1) | BG105548A (es) |
| BR (1) | BR9916006A (es) |
| CA (1) | CA2354266A1 (es) |
| CZ (1) | CZ20012029A3 (es) |
| DE (2) | DE19857009A1 (es) |
| DK (1) | DK1137438T3 (es) |
| EA (1) | EA005136B1 (es) |
| EE (1) | EE200100305A (es) |
| ES (1) | ES2178496T3 (es) |
| HK (1) | HK1041598B (es) |
| HR (1) | HRP20010429A2 (es) |
| HU (1) | HUP0104624A3 (es) |
| IL (1) | IL143586A0 (es) |
| MX (1) | MXPA01005861A (es) |
| NO (1) | NO20012719D0 (es) |
| NZ (1) | NZ511882A (es) |
| PL (1) | PL349336A1 (es) |
| PT (1) | PT1137438E (es) |
| SI (1) | SI1137438T1 (es) |
| SK (1) | SK284842B6 (es) |
| WO (1) | WO2000033876A1 (es) |
| YU (1) | YU39901A (es) |
| ZA (1) | ZA200104815B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040152772A1 (en) * | 2001-03-13 | 2004-08-05 | Erich Eigenbrodt | 1-butyric acid derivatives and the use thereof |
| DE10112924A1 (de) * | 2001-03-13 | 2002-10-02 | Erich Eigenbrodt | 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate |
| GB0123571D0 (en) | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| US20040127435A1 (en) * | 2002-08-02 | 2004-07-01 | Regents Of The University Of California | Uses for inhibitors of inosine monophosphate dehydrogenase |
| EP1534666A1 (de) * | 2002-09-06 | 2005-06-01 | Schebo Biotech AG | Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes |
| WO2005060980A1 (ja) * | 2003-12-24 | 2005-07-07 | Masaakira Shonago | 疾患治療用医薬及び糖尿病治療用医薬 |
| DE102005017592A1 (de) * | 2005-04-16 | 2006-10-19 | Lindner, Jürgen, Dr. med. | Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem |
| AP2516A (en) | 2007-05-03 | 2012-11-26 | Pfizer Ltd | 2-Pyridine carboxamide derivatives as sodium channel modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4127737A1 (de) * | 1991-08-22 | 1993-02-25 | Hoechst Ag | Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen |
| NZ244814A (en) * | 1991-10-23 | 1994-06-27 | Hoechst Ag | N-phenyl-2-cyano-3-hydroxycrotonamide derivatives and pharmaceutical compositions |
| IT1254519B (it) * | 1992-03-16 | 1995-09-25 | Chiesi Farma Spa | Associazioni di composti ad attivita' antivirale |
| DE19539638A1 (de) * | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| WO1998013047A1 (en) * | 1996-09-26 | 1998-04-02 | Williams, James, W. | Improved therapeutic uses of 4-quinoline-carboxylic acid derivatives |
-
1998
- 1998-12-10 DE DE19857009A patent/DE19857009A1/de not_active Withdrawn
-
1999
- 1999-12-01 YU YU39901A patent/YU39901A/sh unknown
- 1999-12-01 CA CA002354266A patent/CA2354266A1/en not_active Abandoned
- 1999-12-01 JP JP2000586366A patent/JP2002531525A/ja not_active Withdrawn
- 1999-12-01 PL PL99349336A patent/PL349336A1/xx not_active Application Discontinuation
- 1999-12-01 PT PT99961041T patent/PT1137438E/pt unknown
- 1999-12-01 SI SI9930063T patent/SI1137438T1/xx unknown
- 1999-12-01 AU AU17793/00A patent/AU766810B2/en not_active Ceased
- 1999-12-01 BR BR9916006-4A patent/BR9916006A/pt not_active IP Right Cessation
- 1999-12-01 EP EP99961041A patent/EP1137438B1/de not_active Expired - Lifetime
- 1999-12-01 HU HU0104624A patent/HUP0104624A3/hu unknown
- 1999-12-01 WO PCT/EP1999/009380 patent/WO2000033876A1/de not_active Application Discontinuation
- 1999-12-01 SK SK788-2001A patent/SK284842B6/sk unknown
- 1999-12-01 AT AT99961041T patent/ATE218370T1/de not_active IP Right Cessation
- 1999-12-01 IL IL14358699A patent/IL143586A0/xx unknown
- 1999-12-01 DE DE59901681T patent/DE59901681D1/de not_active Expired - Fee Related
- 1999-12-01 EA EA200100647A patent/EA005136B1/ru not_active IP Right Cessation
- 1999-12-01 ES ES99961041T patent/ES2178496T3/es not_active Expired - Lifetime
- 1999-12-01 EE EEP200100305A patent/EE200100305A/xx unknown
- 1999-12-01 CZ CZ20012029A patent/CZ20012029A3/cs unknown
- 1999-12-01 CN CNB998142433A patent/CN1189214C/zh not_active Expired - Fee Related
- 1999-12-01 MX MXPA01005861A patent/MXPA01005861A/es active IP Right Grant
- 1999-12-01 NZ NZ511882A patent/NZ511882A/en unknown
- 1999-12-01 DK DK99961041T patent/DK1137438T3/da active
- 1999-12-01 KR KR1020017007176A patent/KR20010080729A/ko not_active Application Discontinuation
- 1999-12-07 AR ARP990106239A patent/AR021577A1/es not_active Application Discontinuation
-
2001
- 2001-05-30 BG BG105548A patent/BG105548A/xx unknown
- 2001-06-01 NO NO20012719A patent/NO20012719D0/no not_active Application Discontinuation
- 2001-06-07 HR HR20010429A patent/HRP20010429A2/hr not_active Application Discontinuation
- 2001-06-13 ZA ZA200104815A patent/ZA200104815B/en unknown
-
2002
- 2002-05-02 HK HK02103282.9A patent/HK1041598B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP055609A (es) | "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor" | |
| UY28041A1 (es) | Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial. | |
| DK1914237T3 (da) | Antivirale fosfonatesterforbindelser | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
| EA200000298A1 (ru) | Агонисты простагландинов и их применение для лечения заболеваний костей | |
| ECSP034642A (es) | Derivados de tetralona como agentes antitumorales | |
| BR0010555A (pt) | Inibidores de neuraminidases | |
| ES2196377T3 (es) | Derivados de naftiridina. | |
| DE60130023D1 (de) | Behandlung der nebenwirkungen von statinen | |
| EA200601002A1 (ru) | 6-алкенил и 6-фенилалкил замещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы | |
| MX9404749A (es) | Heterociclos de fenilo como inhibidores de cox-2. | |
| ATE450265T1 (de) | Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält | |
| ES2194501T3 (es) | Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. | |
| AR036684A1 (es) | Inhibidores de glicogeno sintasa quinasa-3(gsk-3) para tratar glaucoma | |
| BR0305258A (pt) | Inibidores de polimerase de ns5b de hcv | |
| CR10974A (es) | Inhibidores de carboxipeptidasa b plasmatica (divisional) | |
| HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
| AR021577A1 (es) | Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidos | |
| AR046874A1 (es) | Nuevos metodos | |
| ES2150461T3 (es) | Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes. | |
| EA200100140A1 (ru) | Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами | |
| EA200100141A1 (ru) | Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами | |
| UY25220A1 (es) | Nuevas formas polimórficas | |
| MX9300008A (es) | Nucleosidos terapeuticos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |